ERBB2 and non-small cell lung carcinoma: The FDA recently approved a 5.4 mg/kg dose of T-DXd based on data from the clinical studies DESTINY-Lung01 (215) and DESTINY-Lung02 (216) for patients with advanced and metastatic HER2-mutated NSCLC who have received prior systemic therapy.